K5t7S

210. Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. Superior antidepressant efficacy
results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind
study. Int Clin Psychopharmacol. 2010;25(6):305-14.
211. Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, et al. Efficacy of the
novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and
anxiety symptoms in patients with major depressive disorder: a randomized, double-blind
comparison with sertraline. J Clin Psychiatry. 2010 71(2):109-20.
212. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning,
antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin
Psychopharmacol. 2008;28(3):329-33.
213. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive
disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison
with venlafaxine. J Clin Psychiatry. 2007;68(11):1723-32.
214. Kasper S, Corruble E, Hale A, Lemoine P, Montgomery SA, Quera-Salva MA. Antidepressant
efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head
studies without a placebo control. Int Clin Psychopharmacol. 2013;28(1):12-9.
215. Quera-Salva MA, Hajak G, Philip P, Montplaisir J, Keufer-Le Gall S, Laredo J, et al. Comparison
of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in
major depressive disorder patients. Int Clin Psychopharmacol. 2011;26(5):252-62.
216. Martinotti G, Sepede G, Gambi F, Di Iorio G, De Berardis D, Di Nicola M, et al. Agomelatine
versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot
study. J Clin Psychopharmacol. 2012;32(4):487-91.
217. Laux G. The antidepressant agomelatine in daily practice: results of the non-interventional
study VIVALDI. Pharmacopsychiatry. 2012;45(7):284-91.
218. Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression.
Drug Saf. 2011;34(9):709-31.
219. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of
discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms
with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int
Clin Psychopharmacol. 2004;19(5):271-80.
220. Informe mensual. Noviembre 2012. Medicamentos de uso humano Madrid: Agencia Española
de Medicamentos y Productos Sanitarios; [citado 08 feb 2013]. Disponible en: http://www.
aemps.gob.es/informa/informeMensual/2012/noviembre/informe-medicamentos.htm#p3
221. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention
with antidepressant drug treatment in depressive disorders: a systematic review. Lancet.
2003;361(9358):653-61.
222. Hansen R, Gaynes B, Thieda P, Gartlehner G, Deveaugh-Geiss A, Krebs E, et al. Meta-analysis
of major depressive disorder relapse and recurrence with second-generation antidepressants.
Psychiatr Serv. 2008;59(10):1121-30.
223. Reimherr FW, Amsterdam JD, Quitkin FM, Rosenbaum JF, Fava M, Zajecka J, et al. Optimal
length of continuation therapy in depression: a prospective assessment during long-term
fluoxetine treatment. Am J Psychiatry. 1998;155(9):1247-53.
224. Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major
depression. Harv Rev Psychiatry. 1998;5(6):293-306.
225. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression.
Aust N Z J Psychiatry. 2004;38(6):389-407.
250
GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS